Concepedia

Mauro P. Avanzi

MP

Statistics

Publications

14

Citations

1.4K

H-Index

14

Active since

2012

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Moffitt Cancer Center

New York Blood Center

University of Rochester Medical Center

Mauro P. Avanzi is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, immunology, and immunotherapy.

Top concepts

Publications per year

2012–2021

14

Publications

14

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · The Lancet Oncology · 2021 · 574 citations

, , +8

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Mauro P. Avanzi, Oladapo Yeku, Xinghuo Li et al. · Cell Reports · 2018 · 316 citations · Full text

, , +17

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · Blood · 2020 · 105 citations

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

Caron A. Jacobson, Frederick L. Locke, David B. Miklos et al. · Blood · 2018 · 68 citations

Abstract CT055: Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)

Caron A. Jacobson, Jason R. Westin, David B. Miklos et al. · Cancer Research · 2020 · 58 citations

, , +26

1–5 of 14